Peak6 LLC Acquires Shares of 30,000 Roivant Sciences Ltd. (NASDAQ:ROIV)

PEAK6 LLC bought a new stake in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 30,000 shares of the company's stock, valued at approximately $355,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Barclays PLC grew its position in Roivant Sciences by 19.7% in the third quarter. Barclays PLC now owns 459,521 shares of the company's stock worth $5,302,000 after acquiring an additional 75,609 shares during the period. Virtu Financial LLC purchased a new position in shares of Roivant Sciences during the 3rd quarter worth $207,000. Te Ahumairangi Investment Management Ltd grew its holdings in shares of Roivant Sciences by 19.9% during the 3rd quarter. Te Ahumairangi Investment Management Ltd now owns 201,612 shares of the company's stock worth $2,313,000 after purchasing an additional 33,467 shares during the period. Tyro Capital Management LLC increased its position in shares of Roivant Sciences by 0.6% during the 3rd quarter. Tyro Capital Management LLC now owns 1,754,976 shares of the company's stock worth $20,252,000 after purchasing an additional 10,649 shares during the last quarter. Finally, Retirement Systems of Alabama raised its holdings in Roivant Sciences by 26.9% in the 3rd quarter. Retirement Systems of Alabama now owns 530,022 shares of the company's stock valued at $6,116,000 after buying an additional 112,286 shares during the period. Institutional investors and hedge funds own 64.76% of the company's stock.

Insider Activity at Roivant Sciences

In related news, COO Eric Venker sold 218,041 shares of the stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $10.42, for a total value of $2,271,987.22. Following the transaction, the chief operating officer now owns 896,869 shares of the company's stock, valued at $9,345,374.98. This represents a 19.56 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CAO Rakhi Kumar sold 227,500 shares of the stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $10.43, for a total value of $2,372,825.00. Following the completion of the transaction, the chief accounting officer now owns 163,264 shares in the company, valued at approximately $1,702,843.52. The trade was a 58.22 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 1,395,541 shares of company stock valued at $14,922,538 over the last 90 days. 7.90% of the stock is owned by corporate insiders.

Roivant Sciences Stock Performance

Shares of NASDAQ:ROIV traded up $0.01 during trading on Friday, hitting $11.01. The company's stock had a trading volume of 8,016,575 shares, compared to its average volume of 5,445,733. The company has a market capitalization of $7.86 billion, a PE ratio of -73.40 and a beta of 1.25. Roivant Sciences Ltd. has a fifty-two week low of $8.73 and a fifty-two week high of $13.06. The business has a 50 day moving average price of $10.34 and a two-hundred day moving average price of $11.15.

Roivant Sciences (NASDAQ:ROIV - Get Free Report) last released its earnings results on Monday, February 10th. The company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.24) by $0.04. Roivant Sciences had a negative return on equity of 14.05% and a negative net margin of 119.54%. As a group, equities analysts expect that Roivant Sciences Ltd. will post -0.92 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have weighed in on ROIV. HC Wainwright reaffirmed a "buy" rating and set a $18.00 target price on shares of Roivant Sciences in a research note on Monday. Cantor Fitzgerald upgraded Roivant Sciences to a "strong-buy" rating in a report on Tuesday, March 4th.

Roivant Sciences Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.